Customize ASF1B Antibody

Description

Definition and Basic Properties of ASF1B Antibody

ASF1B antibodies are immunoreagents designed to bind specifically to the ASF1B protein, a 19–22 kDa histone chaperone encoded by the ASF1B gene (NCBI Gene ID: 55723) . These antibodies are widely used in techniques such as:

Western blotting (WB)
Immunoprecipitation (IP)
Immunohistochemistry (IHC)
Immunofluorescence (IF/ICC)

Key characteristics include:

Property	Detail
Host Species	Rabbit (polyclonal) or Mouse (monoclonal)
Reactivity	Human, Monkey
Molecular Weight	19–22 kDa
Applications	WB, IP, IHC, IF/ICC, ELISA

Prognostic and Diagnostic Value

ASF1B overexpression correlates with poor prognosis in multiple cancers:

Functional Roles

Cell Cycle Regulation: ASF1B accelerates G1/S phase transition by shortening the G0/G1 phase, as shown in gastric cancer cell lines (AGS, MGC803) .
Immune Modulation:
- Positively correlates with CD8+ T cells, dendritic cells, and Treg infiltration in HCC .
- Linked to elevated PD-1, CTLA-4, and LAG3 expression in exhausted T cells .
Therapeutic Response: High ASF1B expression predicts better response to anti-PD-L1 immunotherapy (ORR: 34% vs. 15%, p < 0.001) .

Immune Microenvironment Correlations

ASF1B expression influences tumor immune landscapes:

Immune Feature	Correlation with ASF1B	Cancer Type
CD8+ T Cell Infiltration	Positive (r = 0.331)	HCC
Treg Infiltration	Positive (r = 0.305)	HCC, STAD
PD-L1 Expression	Positive (r = 0.42)	Pan-cancer
Tumor Mutation Burden	Positive	21 cancer types

Therapeutic and Prognostic Potential

Pan-Cancer Significance: ASF1B is overexpressed in 22 malignancies and correlates with tumor mutation burden (TMB) and microsatellite instability (MSI) .
Targetability: ASF1B knockdown induces apoptosis and cell cycle arrest in cervical cancer models (p < 0.05) .

Mechanistic Insights

Histone Chaperone Activity: ASF1B binds histone H3.3 to facilitate replication-independent nucleosome assembly, critical for β-cell proliferation .
CDK9 Stabilization: In cervical cancer, ASF1B interacts with CDK9, enhancing its stability and promoting tumorigenesis .

Product Specs

Buffer

**Preservative:** 0.03% Proclin 300
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

ASF1B antibody; SGA01 antibody; SGA1 antibody; At5g38110 antibody; F16F17.110Histone chaperone ASF1B antibody; Anti-silencing function protein 1-like protein b antibody; Anti-silencing function 1b protein antibody; Silencing group A protein 1 antibody

Target Names

ASF1B

Uniprot No.

Q9LS09

Target Background

Function

ASF1B is a histone chaperone that plays a crucial role in facilitating histone deposition, exchange, and removal during nucleosome assembly and disassembly processes.

Gene References Into Functions

Research has revealed a significant function of AtASF1A/B in the plant's response to heat stress. PMID: 24548003
ASF1A and ASF1B are subject to regulation by cell cycle progression and are implicated in DNA repair following UV-B irradiation. PMID: 23596192
AtASF1A and AtASF1B proteins exhibit binding affinity for histone H3. Simultaneous knockdown of these proteins disrupts chromatin replication, compromising genome stability and functionality. This leads to the activation of S-phase and DNA repair checkpoints, ultimately resulting in abnormal plant growth and development. PMID: 21251110

Database Links

KEGG: ath:AT5G38110

STRING: 3702.AT5G38110.1

UniGene: At.30436

Protein Families

ASF1 family

Subcellular Location

Nucleus.

Q&A

Here’s a structured FAQ collection for ASF1B antibody research, synthesized from peer-reviewed studies and technical documentation:

Advanced Research Questions

How to resolve contradictory survival data linked to ASF1B expression?
- Context-Dependent Analysis:
  - In LUAD, high ASF1B correlates with worse survival (HR = 1.8, p < 0.01) .
  - In HCC, elevated ASF1B predicts better outcomes (HR = 0.62, p = 0.003) .
- Stratification Strategy:
  
  Cancer Type Survival Trend Proposed Mechanism
  LUAD Worse Proliferation via POLE3/CKS1B
  HCC Better Immune infiltration (CD8+ T cells)
Can ASF1B antibody be used in multiplex assays for tumor microenvironment studies?
- CIBERSORT Integration: Pair IHC with RNA-seq data to correlate ASF1B levels with immune infiltration (e.g., Tregs: r = 0.34, p = 0.008 in TCGA cohorts) .
- Multiplex IHC: Combine with PD-L1/CD8 antibodies to study ASF1B’s role in immunotherapy response .
What epigenetic factors influence ASF1B antibody detection variability?
- Methylation Impact: Hypomethylation at chr19:14,879,632-14,879,832 increases ASF1B expression (β = -0.47, p = 1.2e-5) .
- CNV Considerations: Adjust antibody dilution for samples with chr19q13.42 amplifications .

Cancer Type	Survival Trend	Proposed Mechanism
LUAD	Worse	Proliferation via POLE3/CKS1B
HCC	Better	Immune infiltration (CD8+ T cells)

Mechanistic & Technical Insights

How to design studies probing ASF1B’s role in DNA replication?
- EdU Incorporation: Use ASF1B-knockdown cells (siRNA) to measure S-phase reduction (e.g., 38% decrease in Hep3B cells) .
- Co-IP/MS: Identify interactors like POLE3 and CKS1B using crosslinking (1% formaldehyde) + anti-ASF1B IP .
What controls are critical for ASF1B antibody reproducibility?
- Positive Control: Huh7 cell lysate (high endogenous ASF1B) .
- Negative Control: LO2 normal liver cells (low expression) .
- Buffer Validation: Include 0.5% BSA in PBS to reduce non-specific binding .

Data Interpretation Framework

Table 1: ASF1B-Associated Pathways

Pathway	Enrichment Score	Key Genes
Cell Cycle (G2/M)	NES = 2.1*	CDK1, CCNB1, POLE3
Immune Evasion	NES = 1.8*	PD-L1, CTLA4, FOXP3

*NES: Normalized enrichment score from GSEA .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

ASF1B Antibody